Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0603 • ACR Convergence 2023
Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia
Mehret Birru Talabi¹, Bonnie Bermas², Irene Blanco³, Ashira Blazer⁴, Megan Clowse⁵, Cuoghi Edens⁶, Leslie Pierce⁷, Catherine Wright¹ and Rosalind Ramsey-Goldman³, ¹University of Pittsburgh, Pittsburgh, PA, ²UT Southwestern, Dallas, TX, ³Northwestern University, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY, ⁵Duke University, Chapel Hill, NC, ⁶University of Chicago, Chicago, IL, ⁷University of Pittsburgh, Raleigh, NC
Background/Purpose: Thrombocytopenia (TP) is a common hematologic abnormality in systemic lupus erythematosus (SLE). Severe thrombocytopenia is correlated with disease activity and a worse prognosis of…
Abstract Number: 0799 • ACR Convergence 2023
Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus
Holly Wobma¹, Xianliang Rui², Francesca Alvarez-Calderon², Ulrike Gerdemann², Connor McGuckin², Bruce Blazar³, Victor Tkachev⁴ and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Division of Pediatric Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, ⁴Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
Background/Purpose: Chimeric Antigen Receptor Regulatory T cells (CAR-Tregs) are an emerging strategy to restore immune tolerance during auto- or allo-immune conditions. However, most autoimmune diseases…
Abstract Number: 0896 • ACR Convergence 2023
Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus
Atsushi Manno¹, Tomohiro Honda¹, Chiharu Kuwata², Shiho Ito², Michinori Kadokura¹, Reiko Mizutani³, Shinnosuke Yamada¹ and Yoshiaki Tomimori¹, ¹Daiichi Sankyo Co., Ltd., Shinagawa-ku, Japan, ²Daiichi Sankyo Co., Ltd., Edogawa-ku, Japan, ³Daiichi Sankyo RD Novare Co., Ltd., Edogawa-ku, Japan
Background/Purpose: The centrality of Toll-like receptor 7 (TLR7) to the pathogenesis of systemic lupus erythematosus (SLE) was recently underscored by a report that high TLR7…
Abstract Number: 0915 • ACR Convergence 2023
IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We previously discovered that IL-16 is the urinary protein most strongly correlated with histological activity in lupus nephritis (LN), followed by neutrophil degranulation products…
Abstract Number: 1009 • ACR Convergence 2023
More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid
larry hearld, Jasvinder Singh and Mark Beasley, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the association of the number of implementation strategies for a patient lupus decision aid (DA) with perceived implementation outcomes, and the moderating…
Abstract Number: 1237 • ACR Convergence 2023
The Associations Between Depressive Symptoms and Executive Function and Academic Outcomes in Children with SLE
Hannah Bradfield¹, Paola Sparagana², Elizabeth Sloan¹, Chanhee Jo³, Tracey Wright¹ and Sheryl Frierson², ¹UT Southwestern, Dallas, TX, ²Scottish Rite for Children, Dallas, TX, ³Texas Scottish Rite Hospital, Dallas, TX
Background/Purpose: Children with juvenile-onset SLE (jSLE) have high rates of depression.1-2 Adolescents with depression, but without a chronic illness, have lower academic engagement, efficacy, and…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1474 • ACR Convergence 2023
Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel³, Nayana V³, Ranjan Gupta⁴, Bidyut Das⁵, Parasar Ghosh⁶, Chengappa Kavadichanda⁷, Ashish J Mathew⁸, Manish Rathi⁹, Avinash Jain¹⁰, Sumithra Selvam³ and Amita Aggarwal¹¹, ¹St. John's National Academy of Health Science, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³St. John's Research Institute, Bangalore, India, ⁴All India Institute of Medical Sciences, New Delhi, India, ⁵SCB medical college, Cuttack, India, ⁶Govt of West Bengal, Kolkata, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁸Christian Medical College, Vellore, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
Background/Purpose: Among the cutaneous manifestations of SLE, critical peripheral ischemia (CPI) including digital infarcts and gangrene are considered rare, gangrene occurring only in about 0.2%…
Abstract Number: 1492 • ACR Convergence 2023
Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab
Miles Smith¹, Kevin Thomas¹, Nicolas Dominguez¹, Susan Macwana¹, Wade DeJager¹, Stan Kamp¹, Carla Guthridge¹, Bridget Parrish¹, Cristina Arriens², Judith James¹, Joan Merrill¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK
Background/Purpose: Belimumab, which targets the B Cell activator and survival factor BLyS, is an approved treatment for systemic lupus (SLE) and has demonstrated efficacy in…
Abstract Number: 1510 • ACR Convergence 2023
Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in Women with Systemic Lupus Erythematosus (SLE) Receiving Cyclophosphamide (CYC)
Jun Chu¹, Dania Abid², Zerai Manna¹, Subrata Paul³, Isabel Ochoa³, Yalan Wu³, Sonia Goyal⁴, Syed Ali Abbas Naqvi⁵, Lubna Hooda³ and Sarfaraz Hasni³, ¹Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ²Idaho College of Osteopathic Medicine, Meridian, ID, ³National Institutes of Health, Bethesda, MD, ⁴George Washington University, Washington, DC, ⁵Jewish Hospital of Cincinnati, Cincinnati, OH
Background/Purpose: SLE patients with life-threatening lupus manifestations are often treated with cyclophosphamide (CYC), which has known cytotoxic effects on ovarian reserve. Co-administration of Gonadotropin-releasing hormone…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
Abstract Number: 1837 • ACR Convergence 2023
Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia
Irakli Tskhakaia¹, Pushti Khandwala¹ and Irene Tan², ¹Albert Einstein Medical Center Philadelphia, Philadelphia, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Suicide and depression represent a high burden of morbidity and mortality worldwide. It is well known that fibromyalgia (FM) is associated with mood and…
Abstract Number: 2257 • ACR Convergence 2023
Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019)
Konstantinos Parperis¹ and Bikash Bhattarai², ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Valleywisehealth, Phoenix, AZ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease associated with an increased risk of cardiovascular complications, including acute coronary syndrome (ACS). However, there…
Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.